A free time point model for dynamic contrast enhanced exploration

• Published in: Magnetic resonance imaging Vol. 80; pp. 39 - 49
• Main Authors: Julie, Levebvre, Ikram, Djebali, Mailyn, Perez-Liva, Augustin, Lecler, Afef, Bouchouicha, Joevin, Sourdon, Bentoumi, Isma, Cuenod, Charles-André, Daniel, Balvay
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.07.2021; Elsevier
• Subjects: Convolution; Dynamic systems modeling for prediction; Engineering Sciences; Reliability; Signal synthesis; Convolution; Dynamic systems modeling for prediction; Reliability; Signal synthesis
• ISSN: 0730-725X; 1873-5894
• DOI: 10.1016/j.mri.2021.04.005

Dynamic-Contrast-Enhanced (DCE) Imaging has been widely studied to characterize microcirculatory disorders associated with various diseases. Although numerous studies have demonstrated its diagnostic interest, the physiological interpretation using pharmacokinetic models often remains debatable. Indeed, to be interpretable, a model must provide, at first instance, an accurate description of the DCE data. However, the evaluation and optimization of this accuracy remain rather limited in DCE. Here we established a non-linear Free-Time-Point-Hermite (FTPH) data-description model designed to fit DCE data accurately. Its performance was evaluated on data generated using two contrasting pharmacokinetic microcirculatory hypotheses (MH). The accuracy of data description of the models was evaluated by calculating the mean squared error (QE) from initial and assessed tissue impulse responses. Then, FTPH assessments were provided to blinded observers to evaluate if these assessments allowed observers to identify MH in their data. Regardless of the initial pharmacokinetic model used for data generation, QE was lower than 3% for the noise-free datasets and increased up to 10% for a signal-to-noise-ratio (SNR) of 20. Under SNR = 20, the sensitivity and specificity of the MH identification were over 80%. The performance of the FTPH model was higher than that of the B-Spline model used as a reference. The accuracy of the FTPH model regardless of the initial MH provided an opportunity to have a reference to check the accuracy of other pharmacokinetic models.